[Possible mechanisms of false positive reactions in immunoenzyme analysis].
Explore the source record for details and available documents.
SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
STUDY OBJECTIVE: The Meixner test has been suggested to identify the presence of alpha-amanitin, one of the toxic compounds in Amanita mushrooms. We attempted to determine the detection limit of the Meixner test for alpha-amanitin and to determine the percentage of positive sample interpretation compared with other mushroom indole compounds. METHODS: This was a 2-part in vitro experiment. In part 1, we applied the Meixner test to a series of dilutions of alpha-amanitin (0 microg, 0.8 microg, 1.0 microg, 2.0 microg, and 4.0 microg) on telephone book paper, which were then presented to 5 blinded emergency physicians. We sought to determine the lowest amount of alpha-amanitin that was universally recognized as positive by the physicians (the detection limit). In the second part, 5 emergency physicians were presented simultaneously with 10 Meixner processed samples, including the mushroom indole compounds alpha-amanitin (2 microg and 10 microg), psilocin (20 microL and 60 microL of mushroom extract), 5-hydroxytryptamine (100 microg and 200 microg), and 5-methoxy-N,N-dimethyltryptamine (100 microg and 200 microg), as well as 2 negative controls (20 microL of water and methanol). We determined how likely these other indoles are to be mistaken for a positive alpha-amanitin Meixner reaction result by determining the percentage of positive sample interpretation for each compound and comparing them with the rate for alpha-amanitin. Fisher's exact test was used to determine any significant difference (P<.05) between the samples. RESULTS: The minimum amount of alpha-amanitin that was identified with 100% agreement by testers was 2 microg. For the second part, there was 100% agreement that psilocin gives a positive Meixner test (100% false positive) and a 35% recognition rate of the 5-substituted tryptamine compounds as a positive Meixner test. There was no statistical difference between the interpretation of alpha-amanitin and psilocin, suggesting the test is unable to differentiate between them. CONCLUSION: Although the Meixner test has a good detection limit for toxic amounts of alpha-amanitin, a positive Meixner reaction does not adequately distinguish between alpha-amanitin and other mushroom indoles.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Prisoners are considered to be a high risk population for HIV and HBV infection. Aim of this study was to determine the prevalence of HIV, HBV infection and of the VDRL false positivity by performing screening tests in 496 prisoners of Monza in 1987. About a third of prisoners was HIV infected (with a high prevalence in drug addicts) and about a half had a contact with HBV virus. We observed a very common association between HIV and HBV infections. About ten per cent of HIV infected presented a false positivity for VDRL while one per cent of not infected did. Our data show that in Italian prison HIV and HBV infections are spreadly diffused. False positivity for VDRL may be due not only to drug addiction but also to the immunological variations connected with AIDS.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.